Immuno Oncology Talks Thu, 05 Mar 2026 18:40:07 -0500 https://immuno-oncology-talks.buzzsprout.com en © 2026 Immuno Oncology Talks yes b7bd0b99-1714-59ac-bebb-1440f5781f5a Sanofi episodic false Buzzsprout (https://www.buzzsprout.com) Sanofi https://storage.buzzsprout.com/hxkjq7giu8tza8zp893q3j89yfpz?.jpg Immuno Oncology Talks Looking into the horizon of CAR-T cell therapies Looking into the horizon of CAR-T cell therapies In the current episode of “Immuno Oncology Talks”, we discuss the clinical challenges and future perspectives of CAR-T cells with our experts, from the Oslo University Hospital in Norway, Dr Else Marit Inderberg and Dr Sébastien Wälchli. Dr Inderberg is the head of the immunomonitoring at the hospital and has a research focus on novel immunotherapies, and Dr Wälchli is leading the CAR development platform.




MAT-BE-2400334 (ver.1.0) 04 2024

]]> In the current episode of “Immuno Oncology Talks”, we discuss the clinical challenges and future perspectives of CAR-T cells with our experts, from the Oslo University Hospital in Norway, Dr Else Marit Inderberg and Dr Sébastien Wälchli. Dr Inderberg is the head of the immunomonitoring at the hospital and has a research focus on novel immunotherapies, and Dr Wälchli is leading the CAR development platform.




MAT-BE-2400334 (ver.1.0) 04 2024

]]> Else Marit Inderberg/Sébastien Wälchli Buzzsprout-14847674 Mon, 08 Apr 2024 13:00:00 +0200 2031 CAR-T cell therapies, Else Marit Inderberg, Sébastien Wälchli, immuno oncology, immunotherapy 2 11 full false Oncogenes in relation to immune responses Oncogenes in relation to immune responses In our tenth episode of the “Immuno Oncology Talks”,  we will discuss oncogenes in relation to immune responses with our guest, Professor Juha Klefström, from the Finnish Cancer Institute at the University of Helsinki, Finland. Professor Klefström is an expert in breast cancer biology and immuno-oncology, leading a research group focusing on oncogenes like Myc, in relation to the immune system and the tumour immune micro environment. 

MAT-BE-2400162 (ver.1 ) 02 2024 


]]> In our tenth episode of the “Immuno Oncology Talks”,  we will discuss oncogenes in relation to immune responses with our guest, Professor Juha Klefström, from the Finnish Cancer Institute at the University of Helsinki, Finland. Professor Klefström is an expert in breast cancer biology and immuno-oncology, leading a research group focusing on oncogenes like Myc, in relation to the immune system and the tumour immune micro environment. 

MAT-BE-2400162 (ver.1 ) 02 2024 


]]> Juha Klefström Buzzsprout-14515813 Fri, 16 Feb 2024 14:00:00 +0100 1661 Immuno Oncology Talks, Oncogenes, immune responses, Juha Klefström, Immunotherapy, Immuno-oncology 2 10 full false Cancer Immunotherapy and the role of Microbiome Cancer Immunotherapy and the role of Microbiome In our ninth episode of the “Immuno Oncology Talks”, we will discuss the rapidly evolving field of the microbiome in cancer immunotherapy with our guest, Professor Jeroen Raes, from the Department of Microbiology, Immunology and Transplantation, KU Leuven, Belgium. Professor Raes has established a world leading lab, where they combine large-scale, next-generation sequencing with novel computational approaches to investigate the function and variability of the healthy human microbiome, and to study and compare this with alterations identified in various diseases.

MAT-BE-2300657 (ver. 1.0) June 2023

]]> In our ninth episode of the “Immuno Oncology Talks”, we will discuss the rapidly evolving field of the microbiome in cancer immunotherapy with our guest, Professor Jeroen Raes, from the Department of Microbiology, Immunology and Transplantation, KU Leuven, Belgium. Professor Raes has established a world leading lab, where they combine large-scale, next-generation sequencing with novel computational approaches to investigate the function and variability of the healthy human microbiome, and to study and compare this with alterations identified in various diseases.

MAT-BE-2300657 (ver. 1.0) June 2023

]]> Professor Jeroen Raes Buzzsprout-13098914 Sat, 24 Jun 2023 16:00:00 +0200 1649 Cancer, Immunotherapy, Microbiome 2 9 full false Cancer cell and gene therapies and the challenges to access the market Cancer cell and gene therapies and the challenges to access the market In our eight episode of the “Immuno Oncology Talks”, we will hear about the current challenges of getting cancer cell and gene therapies on the market from a health economic perspective. Our guest, Professor Cornelis Boersma, from University Medical Center Groningen and Open University, in the Netherlands, has an extensive experience within health economics and health care policy. Apart from his previous experience within the pharma industry, he is actively involved as a scientist, consultant and entrepreneur in various national and international initiatives, organizations, networks, and projects in the field of healthcare.

MAT-BE-2300504 (ver 1) 05 2023

]]> In our eight episode of the “Immuno Oncology Talks”, we will hear about the current challenges of getting cancer cell and gene therapies on the market from a health economic perspective. Our guest, Professor Cornelis Boersma, from University Medical Center Groningen and Open University, in the Netherlands, has an extensive experience within health economics and health care policy. Apart from his previous experience within the pharma industry, he is actively involved as a scientist, consultant and entrepreneur in various national and international initiatives, organizations, networks, and projects in the field of healthcare.

MAT-BE-2300504 (ver 1) 05 2023

]]> Professor Cornelis Boersma Buzzsprout-12934794 Sun, 28 May 2023 23:00:00 +0200 1764 Market access challenges, Cancer cell and gene therapies, Professor Cornelis Boersma 2 8 full false Therapeutic RNA vaccines in cancer Immunotherapy Therapeutic RNA vaccines in cancer Immunotherapy This episode, the seventh of our “Immuno Oncology Talks”, will be covering “Therapeutic RNA vaccines in cancer immunotherapy”, with our two guests, Professor Karine Breckpot and Professor Kris Thielemans, from the Laboratory of Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, in Belgium. Both experts have a long background within innovative immunotherapy strategies in cancer, and especially within mRNA vaccination. Professor Thielemans and his team has developed the mRNA based TriMix technology, and initiated several clinical trials in this field.

MAT-BE-2300298 04 2023

]]> This episode, the seventh of our “Immuno Oncology Talks”, will be covering “Therapeutic RNA vaccines in cancer immunotherapy”, with our two guests, Professor Karine Breckpot and Professor Kris Thielemans, from the Laboratory of Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, in Belgium. Both experts have a long background within innovative immunotherapy strategies in cancer, and especially within mRNA vaccination. Professor Thielemans and his team has developed the mRNA based TriMix technology, and initiated several clinical trials in this field.

MAT-BE-2300298 04 2023

]]> Karine Breckpot/Kris Thielemans Buzzsprout-12539852 Wed, 29 Mar 2023 11:00:00 +0200 1795 ImmunoOncology, Therapeutic RNA vaccines, cancer immunotherapy 2 7 full false Non-viral RNA treatment approaches in Cancer Immunotherapy Non-viral RNA treatment approaches in Cancer Immunotherapy In our sixth episode of “Immuno Oncology Talks”, we will discuss non-viral RNA treatment approaches in cancer immunotherapy with our guest, professor Karine Breckpot from the Laboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, in Belgium. Professor Breckpot has a strong background within innovative immunotherapy strategies in cancer, and especially with mRNA technologies as a way to target the immune system.

MAT-BE-2300154 (ver.1.0) 02 2023

]]> In our sixth episode of “Immuno Oncology Talks”, we will discuss non-viral RNA treatment approaches in cancer immunotherapy with our guest, professor Karine Breckpot from the Laboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, in Belgium. Professor Breckpot has a strong background within innovative immunotherapy strategies in cancer, and especially with mRNA technologies as a way to target the immune system.

MAT-BE-2300154 (ver.1.0) 02 2023

]]> Professor Karine Breckpot Buzzsprout-12303577 Wed, 22 Feb 2023 10:00:00 +0100 1785 Non-viral RNA, Cancer immunotherapy, Karine Breckpot, mRNA 2 6 full false Adoptive therapy with engineered T cell receptors Adoptive therapy with engineered T cell receptors In the current, and fifth episode of the “Immuno Oncology Talks”, we discuss adoptive therapy with engineered T cell receptors, with Professor Reno Debets from the Erasmus MC Cancer Institute in the Netherlands. Professor Debets research aims to explore therapeutic strategies by developing and testing adoptive T cell therapy and understand and intervene with the cross-talk between tumor cells and T cells.

MAT-BE-2300064 (Ver 1.0) Jan 2023

]]> In the current, and fifth episode of the “Immuno Oncology Talks”, we discuss adoptive therapy with engineered T cell receptors, with Professor Reno Debets from the Erasmus MC Cancer Institute in the Netherlands. Professor Debets research aims to explore therapeutic strategies by developing and testing adoptive T cell therapy and understand and intervene with the cross-talk between tumor cells and T cells.

MAT-BE-2300064 (Ver 1.0) Jan 2023

]]> Sanofi Buzzsprout-12116538 Wed, 25 Jan 2023 15:00:00 +0100 1772 T-cell receptors, therapy, Professor Reno Debets 1 5 full false Targeting Neutrophils as effector cells in cancer therapy Targeting Neutrophils as effector cells in cancer therapy The fourth episode of “Immuno Oncology Talks”, Professor Marjolein van Egmond from the Amsterdam University Medical Center, in the Netherlands, will shed light on neutrophils as effector cells in cancer therapy. Professor Marjolein van Egmond specializes in the innate immune system and is focusing on elucidating the therapeutic potential of neutrophils in cancer, with a specific interest in IgA and bispecific antibodies to activate the neutrophils. 

MAT-BE-2200978 (ver. 1.0) 12 2022

]]> The fourth episode of “Immuno Oncology Talks”, Professor Marjolein van Egmond from the Amsterdam University Medical Center, in the Netherlands, will shed light on neutrophils as effector cells in cancer therapy. Professor Marjolein van Egmond specializes in the innate immune system and is focusing on elucidating the therapeutic potential of neutrophils in cancer, with a specific interest in IgA and bispecific antibodies to activate the neutrophils. 

MAT-BE-2200978 (ver. 1.0) 12 2022

]]> Marjolein van Egmond Buzzsprout-11863911 Tue, 13 Dec 2022 15:00:00 +0100 1524 1 4 full false Tumor-Infiltrating Lymphocyte Based Adoptive Cellular Therapy Tumor-Infiltrating Lymphocyte Based Adoptive Cellular Therapy In the third episode of the “Immuno Oncology Talks”, we have had the pleasure to discuss tumor infiltrating lymphocytes for adoptive cell therapy with Professor Inge Marie Svane from the National Center for Cancer Immune Therapy in Denmark. Professor Inge Marie Svane has built up this centre into a leading European translational research centre. Apart from her vast expertise is T-cell based adoptive cell therapy, her research also focuses on other cellular therapies, cancer vaccines, and immune regulation.

MAT-BE-2200834 (ver. 1.0) 11 2022

]]> In the third episode of the “Immuno Oncology Talks”, we have had the pleasure to discuss tumor infiltrating lymphocytes for adoptive cell therapy with Professor Inge Marie Svane from the National Center for Cancer Immune Therapy in Denmark. Professor Inge Marie Svane has built up this centre into a leading European translational research centre. Apart from her vast expertise is T-cell based adoptive cell therapy, her research also focuses on other cellular therapies, cancer vaccines, and immune regulation.

MAT-BE-2200834 (ver. 1.0) 11 2022

]]> Sanofi Buzzsprout-11660512 Wed, 09 Nov 2022 06:00:00 +0100 1625 1 3 full false NK cell-based cancer immunotherapies NK cell-based cancer immunotherapies In our second episode of the “Immuno Oncology Talks”, Associate Professor Evren Alici, from the Karolinska Institutet in Sweden, was invited to discuss NK cell-based cancer immunotherapies, accompanied by his colleague Professor Hans-Gustaf Ljunggren. The primary focus of Professor Alici´s research is on novel NK cell-based therapies, and includes generation and testing of genetically engineered NK cells, like chimeric receptor and CAR-NK cells. Associate Professor Alici is also co-director of the NextGenNK Competence Center (https://ki.se/en/research/nextgennk).

MAT-BE-2200747 (ver 1.0) 09 2022

]]> In our second episode of the “Immuno Oncology Talks”, Associate Professor Evren Alici, from the Karolinska Institutet in Sweden, was invited to discuss NK cell-based cancer immunotherapies, accompanied by his colleague Professor Hans-Gustaf Ljunggren. The primary focus of Professor Alici´s research is on novel NK cell-based therapies, and includes generation and testing of genetically engineered NK cells, like chimeric receptor and CAR-NK cells. Associate Professor Alici is also co-director of the NextGenNK Competence Center (https://ki.se/en/research/nextgennk).

MAT-BE-2200747 (ver 1.0) 09 2022

]]> Buzzsprout-11399083 Wed, 28 Sep 2022 13:00:00 +0200 1974 NK cell-based cancer, immunotherapies, Evren Alici, Hans-Gustaf Ljunggren, Immuno Oncology 1 2 full false Biology of Natural Killer (NK) cells Biology of Natural Killer (NK) cells The first episode in the “Immuno Oncology Talks” is about the biology of Natural Killer (NK) cells. The interview is conducted with Professor Hans-Gustaf Ljunggren at Karolinska Institutet in Sweden together with his colleague Associate professor Evren Alici. Professor Ljunggren, who has been studying NK cells for more than 30 years, is director of the NextGenNK Competence Center (https://ki.se/en/research/nextgennk), coordinated by Karolinska Institutet, which has the mission to facilitate development of NK cell-based cancer immunotherapies.

MAT-BE-2200746 (ver 1.0) 09 2022

]]> The first episode in the “Immuno Oncology Talks” is about the biology of Natural Killer (NK) cells. The interview is conducted with Professor Hans-Gustaf Ljunggren at Karolinska Institutet in Sweden together with his colleague Associate professor Evren Alici. Professor Ljunggren, who has been studying NK cells for more than 30 years, is director of the NextGenNK Competence Center (https://ki.se/en/research/nextgennk), coordinated by Karolinska Institutet, which has the mission to facilitate development of NK cell-based cancer immunotherapies.

MAT-BE-2200746 (ver 1.0) 09 2022

]]> Buzzsprout-11399081 Wed, 28 Sep 2022 13:00:00 +0200 1011 Natural Killer (NK) cells,Immuno oncology,Oncology, Evren Alici, Hans-Gustaf Ljunggren 1 1 full false